Sarepta hikes full-year sales estimate for Duchenne drug

Sarepta Therapeutics reported Wednesday that sales of its Duchenne muscular dystrophy drug have picked up momentum since the FDA's controversial approval of the treatment last year. Cambridge-based Sarepta (Nasdaq: SRPT) said that the drug, Exondys 51, had generated $35 million in sales in the second quarter of 2017. That easily exceeded the consensus estimate of analysts, which was around $22 million. Sarepta also raised its guidance for total revenue in 2017, from more tha n $95 million to between…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news